Birgit Steckel-Hamann

Senior Director - External Innovation Cardiometabolic Health at Eli Lilly & Company

Speaker

Accomplished External Innovation Leader with more than 30+ years of experience in large pharma, strategic thinker with deep scientific expertise across R&D pipeline.

Dr. Birgit Steckel-Hamann, Senior Director External Innovation at Eli Lilly holds a PhD in Medicine from the University of Marburg, Germany. She is specialized in Pharmacology and did her PhD study in collaboration with Lilly Diabetes Research Centre in Hamburg. After holding 2 Post Doc positions, working on research projects focussing on Insulin secretion and UV induced skin cancer, she became responsible for leading the Cell Culture and High throughput screening labs at Lilly Diabetes Research Centre in Hamburg and subsequently became responsible for leading Phase 1 and large Phase 3 registration trials in Diabetes Research across Europe. In 2008 Birgit moved on into External Innovation, was industry co-leader of IMI-SUMMIT, a consortium focusing on diabetic complications and became Head of Public Private Partnerships in Europe where she is leading a team overseeing Lillys collaboration with IMI/IHI, the world largest public private partnership in medical research. As a Senior Director in External Innovation Birgit is responsible for Search & Evaluation in Cardiometabolic Health, globally and has been leading the evaluation of a significant number of external collaboration opportunities over the past years. Birgit had several assignments as evaluator and independent expert for EU public funded research programs and serves as Research Director in EFPIA working groups.